AtriCure price target raised to $53 from $49 at Canaccord

Canaccord raised the firm’s price target on AtriCure (ATRC) to $53 from $49 and keeps a Buy rating on the shares. The firm said they beat Q3 estimates and management raised Q4 guidance. The solid quarter was driven broadly across the businesses, aside from minimally invasive ablation/EPi-Sense, which continues to face expected headwinds from PFA adoption. Management remains steadfast that these headwinds will subside, pointing towards its experience in Europe.